Know Cancer

or
forgot password

Transplantation of Highly Purified Haploidentical CD133 Hematopoietic Cells in Children With Severe Combined Immunodeficiency Syndrome


Phase 1
N/A
2 Years
Not Enrolling
Both
Severe Combined Immunodeficiency

Thank you

Trial Information

Transplantation of Highly Purified Haploidentical CD133 Hematopoietic Cells in Children With Severe Combined Immunodeficiency Syndrome


Inclusion Criteria:



- Patient with confirmed severe combined immunodeficiency

- Two years of age or younger

- A suitable matched sibling donor is not available

Exclusion Criteria:

- An available matched sibling donor or a confirmed matched unrelated donor

- Patients with DiGeorge syndrome, Zap70, MHC Class II deficiency, or cartilage-hair
hypoplasia

- Patients with a Lansky performance score of less than 10, evidence of HIV or a
congenital rubella infection or a documented neoplasm

- Patients in whom it is not possible to perform a peripheral blood cell harvest on a
haploidentical family member

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To investigate safety issues related to use of haploidentical highly purified CD133+ hematopoietic cells in patients with SCID

Principal Investigator

Kimberly Kasow, DO

Investigator Role:

Principal Investigator

Investigator Affiliation:

St. Jude Children's Research Hospital

Authority:

United States: Food and Drug Administration

Study ID:

ALSCID

NCT ID:

NCT00152100

Start Date:

February 2004

Completion Date:

August 2007

Related Keywords:

  • Severe Combined Immunodeficiency
  • Severe combined immunodeficiency
  • Transplantation
  • Haploidentical
  • Immunologic Deficiency Syndromes
  • Severe Combined Immunodeficiency

Name

Location

St. Jude Children's Research HospitalMemphis, Tennessee  38105-2794